Funding sources This study was supported by the Swedish Cancer Society, the Swedish Research Council, the Crafoord Foundation, the Berta Kamprad Foundation, the Gunnar Nilsson Cancer Foundation, the Gustav V Jubilee Foundation, BioCare, and Governmental Funding of Clinical Research within the National Health Service.
Clinical and Laboratory Investigations
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort
Version of Record online: 31 OCT 2013
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 169, Issue 5, pages 1049–1055, November 2013
How to Cite
Ekedahl, H., Cirenajwis, H., Harbst, K., Carneiro, A., Nielsen, K., Olsson, H., Lundgren, L., Ingvar, C. and Jönsson, G. (2013), The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. British Journal of Dermatology, 169: 1049–1055. doi: 10.1111/bjd.12504
Conflicts of interest None declared.
- Issue online: 31 OCT 2013
- Version of Record online: 31 OCT 2013
- Accepted manuscript online: 16 JUL 2013 03:04AM EST
- Manuscript Accepted: 26 JUN 2013
- Swedish Cancer Society
- Swedish Research Council
- Crafoord Foundation
- Berta Kamprad Foundation
- Gunnar Nilsson Cancer Foundation
- Gustav V Jubilee Foundation
- National Health Service
|bjd12504-sup-0001-TableS1.docx||Word document||13K||Table S1 BRAF and NRAS mutation status in samples (n = 237) from primary and metastatic melanoma of 203 patients|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.